Imaging hypoxia in gliomas

British Journal of Radiology

Volumn 84, Issue SPEC. ISSUE 2, 2011, Pages

  Mendichovszky, I ^a   Jackson, A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 FLUORO 1 (HYDROXYMETHYL)ETHOXY]METHYL 2 NITROIMIDAZOLE F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; COPPER DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; DEOXYHEMOGLOBIN; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FRP 170; GALLIUM 68; HEAT SHOCK PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; METRONIDAZOLE; METRONIDAZOLE GA 68; METRONIDAZOLE TC 99M; PIMONIDAZOLE; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN; WATER O 15; CONTRAST MEDIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

APOPTOSIS; ARTICLE; ASTROCYTOMA; AUTORADIOGRAPHY; BOLD SIGNAL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; GENE AMPLIFICATION; GENOMIC INSTABILITY; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MICROELECTRODE; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OXYGEN ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN TISSUE LEVEL; PATIENT MONITORING; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOSENSITIVITY; SIGNAL NOISE RATIO; TISSUE OXYGENATION; TUMOR INVASION; ANIMAL; ANOXIA; BRAIN TUMOR; MAGNETIC RESONANCE ANGIOGRAPHY; METHODOLOGY; REVIEW; VASCULARIZATION;

ANIMALS; ANOXIA; BRAIN NEOPLASMS; CONTRAST MEDIA; GLIOMA; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84867214613     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/82292521     Document Type: Article

References (206)

1. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9:10-17. (Pubitemid 39658341)
2. Brown JM. The hypoxic cell: a target for selective cancer therapy\eighteenth Bruce F Cain Memorial Award lecture. Cancer Res 1999;59:5863-70. (Pubitemid 30004940)
3. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9:4-9. (Pubitemid 39658340)
4. Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 1998;78:822-7. (Pubitemid 28418321)
5. Hockel M, Schlenger K, Hockel S, et al. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998;79: 365-9. (Pubitemid 28359734)
6. Sanna K, Rofstad EK. Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 1994;58:258-62. (Pubitemid 24240105)
7. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831-8.
8. Rice GC, Hoy C, Schimke RT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci USA 1986;83:5978-82. (Pubitemid 16000637)
9. Wilson RE, Keng PC, Sutherland RM. Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia. J Natl Cancer Inst 1989;81:1235-40. (Pubitemid 19203147)
10. Cuvier C, Jang A, Hill RP. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 1997;15:19-25. (Pubitemid 27095148)
11. Graham CH, Forsdike J, Fitzgerald CJ, et al. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999;80:617-23. (Pubitemid 29047530)
12. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000;60:916-21. (Pubitemid 30129526)
13. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15. (Pubitemid 26330463)
14. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91. (Pubitemid 26008141)
15. Eckerich C, Zapf S, Fillbrandt R, et al. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer 2007;121:276-83. (Pubitemid 46917695)
16. Jogi A, Ora I, Nilsson H, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 2002;99:7021-6. (Pubitemid 34526250)
17. Raza SM, Lang FF, Aggarwal BB, et al. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 2002;51:2-12; discussion 12-13.
18. Russo CA, Weber TK, Volpe CM, et al. An anoxia inducible endonuclease and enhanced DNA breakage as contri-butors to genomic instability in cancer. Cancer Res 1995;55: 1122-8.
19. Stoler DL, Anderson GR, Russo CA, et al. Anoxia-inducible endonuclease activity as a potential basis of the genomic instability of cancer cells. Cancer Res 1992;52:4372-8.
20. Sutherland RM. Tumor hypoxia and gene expression\implications for malignant progression and therapy. Acta Oncol 1998;37:567-74. (Pubitemid 28557217)
21. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76. (Pubitemid 32219813)
22. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004;3:647-54. (Pubitemid 39193744)
23. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
24. Beasley NJ, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 2002;62:2493-7. (Pubitemid 34462724)
25. Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 2000;20:1527-33. (Pubitemid 30628160)
26. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-14. (Pubitemid 32219818)
27. Leek RD, Talks KL, Pezzella F, et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 2002;62:1326-9. (Pubitemid 34407787)
28. Jones A, Fujiyama C, Blanche C, et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res 2001;7:1263-72. (Pubitemid 32708679)
29. Akakura N, Kobayashi M, Horiuchi I, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001;61: 6548-54. (Pubitemid 32783263)
30. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84. (Pubitemid 36749216)
31. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-16. (Pubitemid 32691934)
32. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
33. Bos R, van der Groep P, Greijer AE, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-81. (Pubitemid 36297788)
34. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61. (Pubitemid 38340304)
35. Ruan H, Su H, Hu L, et al. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 2001;3:255-63. (Pubitemid 32747574)
36. Staller P, Sulitkova J, Lisztwan J, et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307-11. (Pubitemid 37158407)
37. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90. (Pubitemid 28373960)
38. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104-9. (Pubitemid 27343784)
39. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-15. (Pubitemid 28254373)
40. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-15. (Pubitemid 30636574)
41. Jensen RL. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 2006;20:E24.
42. Lal A, Peters H, St Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001;93: 1337-43. (Pubitemid 32910575)
43. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6. (Pubitemid 30131884)
44. Gaddipati JP, Madhavan S, Sidhu GS, et al. Picroliv\a natural product protects cells and regulates the gene expression during hypoxia/reoxygenation. Mol Cell Biochem 1999;194: 271-81. (Pubitemid 29245569)
45. Kimura H, Weisz A, Kurashima Y, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000;95:189-97 (Pubitemid 30017242)
46. Cooper R, Sarioglu S, Sokmen S, et al. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 2003;89:870-6. (Pubitemid 37175810)
47. Potter CP, Harris AL. Diagnostic, prognostic and therapeu-tic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89:2-7. (Pubitemid 36897927)
48. Span PN, Bussink J, Manders P, et al. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 2003;89: 271-6. (Pubitemid 36976315)
49. Flynn JR, Wang L, Gillespie DL, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblas-toma multiforme. Cancer 2008;113:1032-42.
50. Ihnatko R, Kubes M, Takacova M, et al. Extracellular acidosis elevates carbonic anhydrase IX in human glioblas-toma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 2006;29:1025-33.
51. Lund EL, Hog A, Olsen MW, et al. Differential regulation of VEGF, HIF1alpha and angiopoietin-1,-2 and-4 by hypoxia and ionizing radiation in human glioblastoma. Int J Cancer 2004;108:833-8. (Pubitemid 38112610)
52. Sondergaard KL, Hilton DA, Penney M, et al. Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma. Neuropathol Appl Neurobiol 2002;28:210-17. (Pubitemid 34639443)
53. Vidal S, Horvath E, Kovacs K, et al. Expression of hypoxia-inducible factor-1alpha (HIF-1α) in pituitary tumours. Histol Histopathol 2003;18:679-86. (Pubitemid 36773211)
54. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: associa-tion with angiogenesis, invasion, and progression. Cancer 2000;88:2606-18. (Pubitemid 30331970)
55. Belkaid A, Fortier S, Cao J, et al. Necrosis induction in glioblastoma cells reveals a new "bioswitch" function for the M T1-MMP/G6PT signaling axis in proMMP-2 activa-tion versus cell death decision. Neoplasia 2007;9:332-40. (Pubitemid 46608300)
56. Said HM, Polat B, Staab A, et al. Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro. Oncol Rep 2008; 20:413-19.
57. Tsukamoto H, Boado RJ, Pardridge WM, Differential expression in glioblastoma multiforme and cerebral heman-gioblastoma of cytoplasmic proteins that bind two different domains within the 3'-untranslated region of the human glucose transporter 1 (GLUT1) messenger RNA. J Clin Invest 1996;97:2823-32.
58. Said HM, Hagemann C, Staab A, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythro-poietin, VEGF and HIF-1α in human glioma in vitro and in vivo. Radiother Oncol 2007;83:398-405. (Pubitemid 46907985)
59. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8.
60. Gilhuis HJ, Bernse HJ, Jeuken JW, et al. The relationship between genetic aberrations as detected by comparative genomic hybridization and vascularization in glioblastoma xenografts. J Neurooncol 2001;51:121-7. (Pubitemid 32435492)
61. Burton TR, Henson ES, Baijal P, et al. The pro-cell death Bcl-2 family member, BNIP3, is localized to the nucleus of human glial cells: Implications for glioblastoma multiforme tumor cell survival under hypoxia. Int J Cancer 2006;118: 1660-9. (Pubitemid 43376429)
62. Fischer U, Radermacher J, Mayer J, et al. Tumor hypoxia: Impact on gene amplification in glioblastoma. Int J Oncol 2008;33:509-15.
63. Rak J, Filmus J, Finkenzeller G, et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995;14: 263-77. (Pubitemid 26027930)
64. Giaccia AJ. Hypoxic stress proteins: survival of the fittest. Semin Radiat Oncol 1996;6:46-58. (Pubitemid 26029373)
65. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64. (Pubitemid 26272076)
66. Kerbel RS, Viloria-Petit A, Okada F, et al. Establishing a link between oncogenes and tumor angiogenesis. Mol Med 1998;4:286-95. (Pubitemid 28361654)
67. Louis DN, Gusella JF. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 1995;11:412-15.
68. Li JL, Sainson RC, Shi W, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67:11244-53. (Pubitemid 350248550)
69. Blasberg RG, Kobayashi T, Horowitz M, et al. Regional blood flow in ethylnitrosourea-induced brain tumors. Ann Neurol 1983;14:189-201. (Pubitemid 13030274)
70. Groothuis DR, Pasternak JF, Fischer JM, et al. Regional measurements of blood flow in experimental RG-2 rat gliomas. Cancer Res 1983;43:3362-7. (Pubitemid 13061598)
71. Hossman KA, Bloink M. Blood flow and regulation of blood flow in experimental peritumoral edema. Stroke 1981;12: 211-17.
72. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-58.
73. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. Cancer Treat Res 2004;117:249-62.
74. Groshar D, McEwan AJ, Parliament MB, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med 1993; 34:885-8. (Pubitemid 23174604)
75. Parliament MB, Franko AJ, Allalunis-Turner MJ, et al. Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption. Br J Cancer 1997;75:311-18. (Pubitemid 27051043)
76. Rampling R, Cruickshank G, Lewis AD, et al. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994;29:427-31. (Pubitemid 24187904)
77. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromi-sonidazole. J Nucl Med 1992;33:2133-7
78. Raza SM, Fuller GN, Rhee CH, et al. Identification of necrosis-associated genes in glioblastoma by cDNA micro-array analysis. Clin Cancer Res 2004;10:212-21. (Pubitemid 38114182)
79. Rong Y, Durden DL, Van Meir EG, et al. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006;65:529-39. (Pubitemid 44288937)
80. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extra-cellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004;64:920-7. (Pubitemid 38176893)
81. Zagzag D, Esencay M, Mendez O, et al. Hypoxia-and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol 2008;173:545-60.
82. Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006;86:1221-32. (Pubitemid 44789912)
83. Elstner A, Holtkamp N, von Deimling A. Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. Clin Exp Metastasis 2007;24:57-66. (Pubitemid 46569338)
84. Mirimanoff RO. The evolution of chemoradiation for glioblastoma: a modern success story. Curr Oncol Rep 2006;8:50-3.
85. Stupp R, Weber DC The role of radio-and chemotherapy in glioblastoma. Onkologie 2005;28:315-17.
86. Chen Z, Htay A, Dos Santos W, et al. In vitro, angiogenesis by human umbilical vein endothelial cells (HUVEC) induced by three-dimensional co-culture with glioblastoma cells. J Neurooncol 2009;92:121-8.
87. Merighi S, Benini A, Mirandola P, et al. Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol 2007;72:162-72. (Pubitemid 46998535)
88. Ezhilarasan R, Mohanam I, Govindarajan K, et al. Glioma cells suppress hypoxia-induced endothelial cell apoptosis and promote the angiogenic process. Int J Oncol 2007;30: 701-7.
89. Leibel SA, Scott CB, Loeffler JS. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol 1994;21:198-219. (Pubitemid 24125959)
90. Stieber VW, Mehta MP. Advances in radiation therapy for brain tumors. Neurol Clin 2007;25:1005-33, ix. (Pubitemid 47600573)
91. Padhani AR, Krohn KA, Lewis JS, et al. Imaging oxygena-tion of human tumours. Eur Radiol 2007;17:861-72.
92. Bloom HJ. Intracranial tumors: response and resistance to therapeutic endeavors, 1970-1980. Int J Radiat Oncol Biol Phys 1982;8:1083-113. (Pubitemid 12053183)
93. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26: 2839-45.
94. Spence AM, Muzi M, Swanson KR, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F] fluoromi-sonidazole positron emission tomography before radio-therapy: correlation with time to progression and survival. Clin Cancer Res 2008;14:2623-30.
95. Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003;67:3-15. (Pubitemid 36575463)
96. Williams KJ, Parker CA, Stratford IJ. Exogenous and endogenous markers of tumour oxygenation status: defini-tive markers of tumour hypoxia? Adv Exp Med Biol 2005;566:285-94. (Pubitemid 43779514)
97. Kaynar MY, Sanus GZ, Hnimoglu H, et al. Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci 2008;15:1036-42.
98. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 1993;53:5721-6. (Pubitemid 23360277)
99. Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 1998;253:743-50. (Pubitemid 28223543)
100. Rijken PF, Bernsen HJ, Peters JP, et al. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 2000;48:571-82.
101. Raleigh JA, Chou SC, Arteel GE, et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999;151:580-9. (Pubitemid 29381608)
102. Wijffels KI, Kaanders JH, Rijken PF, et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 2000;83: 674-83. (Pubitemid 30636312)
103. Raleigh JA, Chou SC, Calkins-Adams DP, et al. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin Cancer Res 2000;6: 855-62. (Pubitemid 30159340)
104. Vukovic V, Haugland HK, Nicklee T, et al. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001;61:7394-8. (Pubitemid 32995022)
105. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757. (Pubitemid 44832019)
106. Bentzen L, Keiding S, Nordsmark M, et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003;67:339-44. (Pubitemid 36831089)
107. Collingridge DR, Piepmeier JM, Rockwell S, et al. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 1999;53:127-31.
108. Helmlinger G, Yuan F, Dellian M, et al. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997;3:177-82. (Pubitemid 27064702)
109. Kallinowski F, Zander R, Hoeckel M, et al. Tumor tissue oxygenation as evaluated by computerized-pO2-histography Int J Radiat Oncol Biol Phys 1990;19:953-61.
110. Kayama T, Yoshimoto T, Fujimoto S, et al. Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg 1991;74:55-9.
111. Doll CM, Milosevic M, Pintilie M, et al. Estimating hypoxic status in human tumors: a simulation using Eppendorf oxygen probe data in cervical cancer patients. Int J Radiat Oncol Biol Phys 2003;55:1239-46. (Pubitemid 36338290)
112. Riesterer O, Milas L, Ang KK. Use of molecular biomar-kers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 2007;25:4075-83. (Pubitemid 47495867)
113. Vordermark D, Brown JM. Evaluation of hypoxia-inducible factor-1alpha (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. Int J Radiat Oncol Biol Phys 2003; 56:1184-93. (Pubitemid 36794054)
114. Airley RE, Loncaster J, Raleigh JA, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 2003;104:85-91. (Pubitemid 36184150)
115. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carci-noma of the cervix. Cancer Res 2001;61:6394-9. (Pubitemid 32783244)
116. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhy-drases. Cancer Res 2000;60:7075-83. (Pubitemid 32059187)
117. Olive PL, Aquino-Parsons C, MacPhail SH, et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001;61:8924-9. (Pubitemid 34013910)
118. Brown JM, Le QT. Tumor hypoxia is important in radiotherapy, but how should we measure it? Int J Radiat Oncol Biol Phys 2002;54:1299-301. (Pubitemid 35380027)
119. Bruehlmeier M, Roelcke U, Schubiger PA, et al. Assess-ment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 2004;45:1851-9. (Pubitemid 47618442)
120. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-42. (Pubitemid 32112868)
121. Tochon-Danguy HJ, Sachinidis JI, Chan F, et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002;29:191-7. (Pubitemid 34127952)
122. Rasey JS, Casciari JJ, Hofstrand PD, et al. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 2000;153:84-92. (Pubitemid 30117087)
123. Rasey JS, Hofstrand PD, Chin LK, et al. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;40:1072-9. (Pubitemid 29269230)
124. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomo-graphy of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
125. Martin GV, Caldwell JH, Rasey JS, et al. Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium. J Nucl Med 1989;30:194-201. (Pubitemid 19048514)
126. Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 2009;69:4502-9.
127. Hicks RJ, Rischin D, Fisher R, et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradia-tion incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005;32:1384-91. (Pubitemid 41746841)
128. Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006;47:410-18. (Pubitemid 46768482)
129. Troost EG, Laverman P, Kaanders JH, et al. Imaging hypoxia after oxygenation-modification: comparing [18F] FMISO autoradiography with pimonidazole immunohis-tochemistry in human xenograft tumors. Radiother Oncol 2006;80:157-64. (Pubitemid 44314018)
130. Lewis JS, McCarthy DW, McCarthy TJ, et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999;40:177-83. (Pubitemid 29044189)
131. Yuan H, Schroeder T, Bowsher JE, et al. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4- methylthiosemicarbazone). J Nucl Med 2006;47:989-98. (Pubitemid 46939952)
132. Lewis JS, Sharp TL, Laforest R, et al. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001;42:655-61. (Pubitemid 32298288)
133. Obata A, Yoshimi E, Waki A, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4- methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001;15:499-504. (Pubitemid 34131947)
134. Blankenberg FG, Eckelman WC, Strauss HW, et al. Role of radionuclide imaging in trials of antiangiogenic therapy. Acad Radiol 2000;7:851-67.
135. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233-8. (Pubitemid 36338289)
136. Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60. (Pubitemid 27339632)
137. Ito M, Yang DJ, Mawlawi O, et al. PET and planar imaging of tumor hypoxia with labeled metronidazole. Acad Radiol 2006;13:598-609.
138. Mallia MB, Subramanian S, Banerjee S, et al. Evaluation of 99mTc(CO)3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia. Bioorg Med Chem 2006;14:7666-70. (Pubitemid 44584727)
139. Shibahara I, Kumabe T, Kanamori M, et al. Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[(18)F] fluoro-1-[hydroxy-methyl]ethoxy)methyl-2-nitroimidazole, a new (18)F-labeled 2-nitroimidazole analog. J Neurosurg 2010;113:358-68.
140. Abramovitch R, Dafni H, Smouha E, et al. In vivo prediction of vascular susceptibility to vascular suscept-ibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 1999;59:5012-16. (Pubitemid 29472908)
141. Abramovitch R, Marikovsky M, Meir G, et al. Stimulation of tumour angiogenesis by proximal wounds: spatial and temporal analysis by MRI. Br J Cancer 1998;77:440-7. (Pubitemid 28044049)
142. Brasch R, Pham C, Shames D, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7:68-74. (Pubitemid 28365640)
143. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998; 171:941-9. (Pubitemid 28449949)
144. Gossmann A, Okuhata Y, Shames DM, et al. Prostate cancer tumor grade differentiation with dynamic con-trast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media\preliminary experience. Radiology 1999;213:265-72. (Pubitemid 29470436)
145. Griffiths JR, Taylor NJ, Howe FA, et al. The response of human tumors to carbogen breathing, monitored by Gradient-Recalled Echo Magnetic Resonance Imaging. Int J Radiat Oncol Biol Phys 1997;39:697-701. (Pubitemid 27441439)
146. 2*-weighted MR imaging. Radiology 1999;211:791-8. (Pubitemid 29249482)
147. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901-9. (Pubitemid 30262837)
148. McMillan KM, Rogers BP, Field AS, et al. Physiologic characterisation of glioblastoma multiforme using MRI-based hypoxia mapping, chemical shift imaging, perfusion and diffusion maps. J Clin Neurosci 2006;13:811-17 (Pubitemid 44415476)
149. Bhujwalla ZM, Artemov D, Natarajan K, et al. Vascular differences detected by MRI for metastatic versus non-metastatic breast and prostate cancer xenografts. Neoplasia 2001;3:143-53. (Pubitemid 32410355)
150. Fisher MJ, Adamson PC Anti-angiogenic agents for the treatment of brain tumors. Neuroimaging Clin N Am 2002;12:477-99. (Pubitemid 36015487)
151. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713-25. (Pubitemid 36749220)
152. Pathak AP, Schmainda KM, Ward BD, et al. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med 2001;46:735-47. (Pubitemid 32906143)
153. Pham CD, Roberts TP, van Bruggen N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;16:225-30. (Pubitemid 28211008)
154. Su MY, Najafi AA, Nalcioglu O. Regional comparison of tumor vascularity and permeability parameters measured by albumin-Gd-DTPA and Gd-DTPA. Magn Reson Med 1995;34:402-11.
155. Turetschek K, Roberts TP, Floyd E, et al. Tumor microvas-cular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging 2001;13:882-8. (Pubitemid 32479946)
156. Howe FA, Robinson SP, McIntyre DJ, et al. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001;14:497-506. (Pubitemid 33150238)
157. Robinson SP, Rijken PF, Howe FA, et al. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 2003;17:445-54. (Pubitemid 36396947)
158. Kostourou V, Robinson SP, Whitley GS, et al. Effects of overexpression of dimethylarginine dimethylaminohydro-lase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 2003;63:4960-6. (Pubitemid 37022632)
159. Taylor NJ, Baddeley H, Goodchild KA, et al. BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 2001;14:156-63. (Pubitemid 32709475)
160. Rijpkema M, Kaanders JH, Joosten FB, et al. Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2002;53:1185-91. (Pubitemid 34787854)
161. 2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson Imaging 2004;19:482-8. (Pubitemid 38437157)
162. Neeman M. Functional and molecular MR imaging of angiogenesis: seeing the target, seeing it work. J Cell Biochem Suppl 2002;39:11-17. (Pubitemid 36176550)
163. Dunn JF, O'Hara JA, Zaim-Wadghiri Y, et al. Changes in oxygenation of intracranial tumors with carbogen: a BOLD MRI and EPR oximetry study. J Magn Reson Imaging 2002;16:511-21. (Pubitemid 35257757)
164. Hsu YY, Chang CN, Jung SM, et al. Blood oxygenation level-dependent MRI of cerebral gliomas during breath holding. J Magn Reson Imaging 2004;19:160-7.
165. Rauscher A, Sedlacik J, Fitzek C, et al. High resolution susceptibility weighted MR-imaging of brain tumors during the application of a gaseous agent. Rofo 2005; 177:1065-9. (Pubitemid 41159018)
166. Chen CM, Hou BL, Holodny AI. Effect of age and tumor grade on BOLD functional MR imaging in preoperative assessment ofpatients with glioma. Radiology 2008;248:971-8.
167. Feldman SC, Chu D, Schulder M, et al. The blood oxygen level-dependent functional MR imaging signal can be used to identify brain tumors and distinguish them from normal tissue. AJNR Am J Neuroradiol 2009;30:389-95.
168. Gore JC. The meaning and significance of relaxation in NMR. Radiology 1982;142:243.
169. Edelman RR, Hatabu H, Tadamura E, et al. Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging. Nature Medicine 1996;2:1236-9. (Pubitemid 26375408)
170. Tadamura E, Hatabu H, Li W, et al. Effect of oxygen inhalation on relaxation times in various tissues. J Magn Reson Imaging 1997;7:220-5. (Pubitemid 28365664)
171. Jones RA, Ries M, Moonen CTW, et al. Imaging the changes in renal T-1 induced by the inhalation of pure oxygen: A feasibility study. Magn Reson Med 2002;47:728-35. (Pubitemid 34263786)
172. O'Connor JPB, Jackson A, Buonaccorsi GA, et al. Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times. Magn Reson Med 2007;58:490-6. (Pubitemid 350154959)
173. McGrath DM, Naish JH, O'Connor JPB, et al. Oxygen-induced changes in longitudinal relaxation times in skeletal muscle. Magn Reson Imaging 2008;26:221-7 (Pubitemid 351146683)
174. Ohno Y, Hatabu H, Takenaka D, et al. Oxygen-enhanced MR ventilation imaging of the lung: Preliminary clinical experi-ence in 25 subjects. AJR Am J Roentgenol 2001;177:185-94. (Pubitemid 32578077)
175. Arnold JFT, Kotas M, Fidler F, et al. Quantitative regional oxygen transfer Imaging of the human lung. J Magn Reson Imaging 2007;26:637-45. (Pubitemid 350194586)
176. Thulborn KR, Waterton JC, Matthews PM, et al. Oxygenation dependence of the transverse relaxation time of water protons in whole blood at high field. Biochim Biophys Acta 1982;714:265-70. (Pubitemid 12134309)
177. O'Connor JP, Naish JH, Jackson A, et al. Comparison of normal tissue R1 and R*2 modulation by oxygen and carbogen. Magn Reson Med 2009;61:75-83.
178. O'Connor JP, Naish JH, Parker GJ, et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009;75:1209-15.
179. Zhou HA, Mason RP, Zhao D. Integrated MRI Approaches to Interrogate Tumor Oxygenation and Vascular Perfusion of Orthotopic Brain Tumors in a Mouse Model. in ISMRM-ESMRMB Joint Annual Meeting. 2010. Stockholm, Sweden.
180. Compostella A, Tosoni A, Blatt V, et al. Prognostic factors for anaplastic astrocytomas. J Neurooncol2007;81:295-303. (Pubitemid 46165334)
181. Rieger J, Bahr O, Muller K, et al. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 2010;99:49-56.
182. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32. (Pubitemid 29463104)
183. Dewhirst MW, Tso CY, Oliver R, et al. Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys 1989;17:91-9. (Pubitemid 19173243)
184. Dewhirst MW, Klitzman B, Braun RD, et al. Review of methods used to study oxygen transport at the micro-circulatory level. Int J Cancer 2000;90:237-55.
185. Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the signifi-cance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132. (Pubitemid 28554861)
186. Foo SS, Abbott DF, Lawrentschuk N, et al. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 2004;6:291-305. (Pubitemid 39263636)
187. Goda F, Bacic G, O'Hara JA, et al. The relationship between partial pressure of oxygen and perfusion in two murine tumors after X-ray irradiation: a combined gadopentetate dimeglumine dynamic magnetic resonance imaging and in vivo electron paramagnetic resonance oximetry study. Cancer Res 1996;56:3344-9. (Pubitemid 26242987)
188. Hawighorst H, Knapstein PG, Knopp MV, et al. Uterine cervical carcinoma: comparison of standard and pharma-cokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 1998;58:3598-602. (Pubitemid 28376557)
189. Cooper RA, Carrington BM, Loncaster JA, et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000;57:53-9.
190. Lyng H, Vorren AO, Sundfor K, et al. Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. J Magn Reson Imaging 2001;14:750-6. (Pubitemid 33101534)
191. Mayr NA, Yuh WT, Arnholt JC, et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 2000; 12:1027-33.
192. Yamashita Y, Baba T, Baba Y, et al. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharma-cokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 2000;216:803-9. (Pubitemid 30660858)
193. Loncaster JA, Carrington BM, Sykes JR, et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002;54:759-67.
194. 1w DCE-MRI. Phys Med Biol 2005;50:4209-23. (Pubitemid 41225266)
195. Kaminogo M, Ishimaru H, Morikawa M, et al. Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain. Neuroradiology 2001;43: 353-63. (Pubitemid 32452069)
196. Poptani H, Gupta RK, Roy R, et al. Characterization of intracranial mass lesions with in vivo proton MR spectro-scopy. AJNR Am J Neuroradiol 1995;16:1593-603.
197. Barba I, Cabanas ME, Arus C. The relationship between nuclear magnetic resonance-visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res 1999;59:1861-8. (Pubitemid 29186158)
198. Lim M, Cheshier S, Steinberg GK. New vessel formation in the central nervous system during tumor growth, vascular malformations, and Moyamoya. Curr Neurovasc Res 2006;3:237-45. (Pubitemid 44198476)
199. Remy C, Fouilhe N, Barba I, et al. Evidence that mobile lipids detected in rat brain glioma by 1H nuclear magnetic resonance correspond to lipid droplets. Cancer Res 1997;57:407-14. (Pubitemid 27081656)
200. Fayed N, Morales H, Modrego PJ, et al. Contrast/Noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate low-grade from high-grade cerebral gliomas. Acad Radiol 2006;13:728-37
201. Howe FA, Opstad KS. 1H MR spectroscopy of brain tumours and masses. NMR Biomed 2003;16:123-31.
202. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49:223-32. (Pubitemid 36159858)
203. Walecki J, Tarasow E, Kubas B, et al. Hydrogen-1 MR spectroscopy of the peritumoral zone in patients with cerebral glioma: assessment of the value of the method. Acad Radiol 2003;10:145-53. (Pubitemid 36150967)
204. Li X, Vigneron DB, Cha S, et al. Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. AJNR Am J Neuroradiol2005;26:760-9. (Pubitemid 43079765)
205. Jenkinson MD, Smith TS, Joyce K, et al. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005;64:2085-9. (Pubitemid 40880999)
206. Rijpkema M, Schuuring J, van der Meulen Y, et al. Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 2003; 16:12-18. (Pubitemid 36284831)